Flag of the European Union EU Clinical Trials Register Help

Clinical trials for End Stage Liver Disease

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   43881   clinical trials with a EudraCT protocol, of which   7295   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    898 result(s) found for: End Stage Liver Disease. Displaying page 1 of 45.
    1  2  3  4  5  6  7  8  9  Next» Last»»
    EudraCT Number: 2015-000963-15 Sponsor Protocol Number: MATCH0.1 Start Date*: 2016-01-19
    Sponsor Name:University of Edinburgh [...]
    1. University of Edinburgh
    2. NHS Lothian
    Full Title: MAcrophage Therapy for Liver Cirrhosis (MATCH)
    Medical condition: Liver Cirrhosis
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004871 10024667 Liver cirrhosis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA)
    Trial results: (No results available)
    EudraCT Number: 2018-004431-79 Sponsor Protocol Number: CC-90001-NASH-001 Start Date*: 2019-11-15
    Sponsor Name:Celgene Corporation
    Full Title: A PHASE 2, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER, DOSEFINDING STUDY TO EVALUATE THE EFFICACY AND SAFETY OF CC-90001 IN SUBJECTS WITH NONALCOHOLIC STEATOHEPATITIS (NASH) AND LIVE...
    Medical condition: Confirmed diagnosis of NASH and Stage 3 or Stage 4 fibrosis based upon the NASH Clinical Research Network (CRN) Histologic Scoring System and a nonalcoholic fatty liver disease (NAFLD) Activity Sco...
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA) FR (Prematurely Ended) ES (Ongoing) PL (Completed)
    Trial results: View results
    EudraCT Number: 2014-001552-29 Sponsor Protocol Number: 1271/2014 Start Date*: 2014-06-20
    Sponsor Name:Medizinische Universität Wien, Abteilung für Anästhesie und allgemeine Intensivmedizin
    Full Title: Determination of the minimal alveolar concentration of Sevoflurane in patient with end stage liver disease
    Medical condition: Orthotopic liver transplantation (OLT) is the only therapy for patients with liver failure. These patients have reduced anesthetic requirements compared with healthy patients. Sevoflurane has prove...
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: AT (Completed)
    Trial results: View results
    EudraCT Number: 2010-022012-40 Sponsor Protocol Number: PA-CL-05B Start Date*: 2011-02-21
    Sponsor Name:Vifor (International) Inc.
    Full Title: An Open-label, Randomised, Active-controlled, Parallel Group, Multicentre Phase 3 Study to Investigate the Long-term Safety, Tolerability and Efficacy of PA21 compared with Sevelamer Carbonate in D...
    Medical condition: Control of hyperphosphataemia in patients with chronic kidney disease on dialysis
    Disease: Version SOC Term Classification Code Term Level
    15.0 10038359 - Renal and urinary disorders 10064848 Chronic kidney disease LLT
    15.0 10027433 - Metabolism and nutrition disorders 10020712 Hyperphosphatemia LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) CZ (Completed) LV (Completed) LT (Completed) SE (Completed) AT (Completed) DE (Completed) BE (Completed)
    Trial results: View results
    EudraCT Number: 2014-003164-21 Sponsor Protocol Number: 652-2-203 Start Date*: 2015-01-05
    Sponsor Name:Tobira Therapeutics, Inc., a subsidiary of Allergan plc
    Full Title: Efficacy and Safety Study of Cenicriviroc for the Treatment of Nonalcoholic Steatohepatitis (NASH) in Adult Subjects with Liver Fibrosis
    Medical condition: Nonalcoholic Steatohepatitis
    Disease: Version SOC Term Classification Code Term Level
    20.0 10019805 - Hepatobiliary disorders 10053219 Non-alcoholic steatohepatitis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed) GB (Completed) IT (Completed) DE (Completed) ES (Completed) FR (Completed)
    Trial results: View results
    EudraCT Number: 2009-010335-41 Sponsor Protocol Number: RRK3728 Start Date*: 2009-06-30
    Sponsor Name:University of Birmingham
    Full Title: A MULTICENTRE, PHASE II, OPEN LABEL, RANDOMISED CONTROLLED TRIAL OF REPEATED AUTOLOGOUS INFUSIONS OF G-CSF MOBILISED CD133+ BONE MARROW STEM CELLS IN PATIENTS WITH CIRRHOSIS
    Medical condition: Liver Cirrhosis
    Disease: Version SOC Term Classification Code Term Level
    14.1 10010331 - Congenital, familial and genetic disorders 10001806 Alpha-1 anti-trypsin deficiency PT
    14.1 10019805 - Hepatobiliary disorders 10009211 Cirrhosis liver LLT
    14.1 10019805 - Hepatobiliary disorders 10024667 Liver cirrhosis LLT
    14.1 10019805 - Hepatobiliary disorders 10064844 Compensated cirrhosis LLT
    14.1 10019805 - Hepatobiliary disorders 10019641 Hepatic cirrhosis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2014-005012-42 Sponsor Protocol Number: 747-302 Start Date*: 2016-01-05
    Sponsor Name:Intercept Pharmaceuticals Inc.
    Full Title: A Phase 4, Double Blind, Randomized, Placebo Controlled, Multicenter Study Evaluating the Effect of Obeticholic Acid on Clinical Outcomes in Subjects with Primary Biliary Cholangitis. The COBALT S...
    Medical condition: Primary Biliary Cholangitis
    Disease: Version SOC Term Classification Code Term Level
    21.0 100000004871 10036680 Primary biliary cirrhosis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Completed) LT (Prematurely Ended) AT (Prematurely Ended) BE (Ongoing) DK (Prematurely Ended) FI (Prematurely Ended) GB (GB - no longer in EU/EEA) EE (Prematurely Ended) ES (Prematurely Ended) NL (Prematurely Ended) FR (Ongoing) DE (Completed) BG (Prematurely Ended) PT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2011-005650-54 Sponsor Protocol Number: MD2011.01 Start Date*: 2012-06-04
    Sponsor Name:University Medical Center Groningen
    Full Title: Prothrombin complex concentrate in the reduction of blood loss during otrhotopic liver transplantation.
    Medical condition: liver cirhosis coagulopathy bleeding
    Disease: Version SOC Term Classification Code Term Level
    14.1 10005329 - Blood and lymphatic system disorders 10009802 Coagulopathy PT
    14.1 10042613 - Surgical and medical procedures 10024716 Liver transplantation LLT
    14.1 10022891 - Investigations 10049227 Bleeding time abnormal PT
    14.1 10019805 - Hepatobiliary disorders 10024667 Liver cirrhosis LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: FI (Ongoing) NL (Ongoing) BE (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2005-004505-29 Sponsor Protocol Number: 2676 Start Date*: 2008-05-15
    Sponsor Name:Royal Marsden NHS Trust
    Full Title: Phase II clinical trial of capecitabine and oxaliplatin plus bevacizumab as neoadjuvant treatment for patients with previously untreated unresectable liver-only metastases from colorectal cancer
    Medical condition: Metastatic colorectal adenocarcinoma with metastases involving the liver only
    Disease: Version SOC Term Classification Code Term Level
    8.1 10010035 Colorectal cancer stage IV PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2015-002560-16 Sponsor Protocol Number: 747-303 Start Date*: 2015-12-10
    Sponsor Name:Intercept Pharmaceuticals Inc.
    Full Title: A Phase 3, Double-Blind, Randomized, Long-Term, Placebo-Controlled, Multicenter Study Evaluating the Safety and Efficacy of Obeticholic Acid in Subjects with Nonalcoholic Steatohepatitis
    Medical condition: Nonalcoholic steatohepatitis
    Disease: Version SOC Term Classification Code Term Level
    22.0 100000004871 10029530 Non-alcoholic fatty liver LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA) DE (Prematurely Ended) AT (Completed) SE (Completed) BE (Completed) DK (Completed) ES (Prematurely Ended) FI (Completed) PT (Prematurely Ended) HU (Completed) PL (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2019-003932-22 Sponsor Protocol Number: IM025-017 Start Date*: 2022-10-04
    Sponsor Name:Bristol-Myers Squibb International Corporation
    Full Title: A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multiple-Dose Phase 2 Study to Evaluate the Efficacy and Safety of BMS-986263 in Adults with Compensated Cirrhosis from Nonalcoholic ...
    Medical condition: Compensated Cirrhosis from Nonalcoholic Steatohepatitis (NASH)
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004871 10019669 Hepatic fibrosis and cirrhosis HLT
    20.1 100000004871 10064844 Compensated cirrhosis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed) BE (Completed) DE (Completed) IT (Ongoing) NL (Completed)
    Trial results: (No results available)
    EudraCT Number: 2009-016761-29 Sponsor Protocol Number: HE2013 Start Date*: 2010-05-14
    Sponsor Name:University of Birmingham
    Full Title: A 48-WEEK PHASE II, RANDOMISED, DOUBLE BLINDED PLACEBO CONTROLLED, PARALLEL-GROUP, MULTI-CENTRE TRIAL ON LIRAGLUTIDE’S SAFETY, EFFICACY AND ACTION ON LIVER HISTOLOGY AND METABOLISM IN OVERWEIGHT PA...
    Medical condition: Non-alcoholic steatohepatits (NASH)
    Disease: Version SOC Term Classification Code Term Level
    14.0 10027433 - Metabolism and nutrition disorders 10012601 Diabetes mellitus PT
    14.0 10019805 - Hepatobiliary disorders 10024670 Liver disorder PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2009-012570-13 Sponsor Protocol Number: BAY73-4506/14596 Start Date*: 2009-08-25
    Sponsor Name:Bayer HealthCare AG, D51368 Leverkusen
    Full Title: An uncontrolled open label multicenter phase II safety study of BAY 73-4506 in patients with hepatocellular carcinoma (HCC)
    Medical condition: Hepatocellular carcinoma, in patients who have failed (experienced radiological progression) previous treatment cancer
    Disease: Version SOC Term Classification Code Term Level
    14.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10049010 Carcinoma hepatocellular LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) ES (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2012-002488-88 Sponsor Protocol Number: GS-US-321-0105 Start Date*: 2013-07-29
    Sponsor Name:Gilead Sciences Inc
    Full Title: A Phase 2b, Dose-Ranging, Randomized, Double-Blind, Placebo-Controlled Trial Evaluating the Safety and Efficacy of GS-6624, a Monoclonal Antibody Against Lysyl Oxidase-Like 2 (LOXL2), in Subjects w...
    Medical condition: Advanced Liver Fibrosis Secondary to Non-Alcoholic Steatohepatitis (NASH)
    Disease: Version SOC Term Classification Code Term Level
    14.1 10019805 - Hepatobiliary disorders 10053219 Non-alcoholic steatohepatitis PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: IT (Completed) DE (Prematurely Ended) GB (Prematurely Ended) ES (Completed) BE (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2014-005097-11 Sponsor Protocol Number: ETOP6-14 Start Date*: 2015-08-03
    Sponsor Name:ETOP (European Thoracic Oncology Platform)
    Full Title: A phase II trial evaluating the safety and efficacy of the addition of concurrent anti-PD-1 nivolumab to standard first-line chemotherapy and radiotherapy in locally advanced stage IIIA/B Non-Small...
    Medical condition: locally advanced stage IIIA/B NSCLC
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10029520 Non-small cell lung cancer stage IIIA PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10029521 Non-small cell lung cancer stage IIIB PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed) ES (Completed) DE (Completed) NL (Completed)
    Trial results: View results
    EudraCT Number: 2011-001084-42 Sponsor Protocol Number: 9090-08 Start Date*: 2011-07-15
    Sponsor Name:Synta Pharmaceuticals Corp.
    Full Title: A Randomized, Phase IIb/III Study of Ganetespib (STA-9090) in Combination with Docetaxel versus Docetaxel alone in Subjects with Stage IIIb or IV Non-Small Cell Lung Cancer
    Medical condition: Non-Small Cell Lung Cancer
    Disease: Version SOC Term Classification Code Term Level
    14.1 100000004864 10025054 Lung cancer non-small cell stage IIIB LLT
    14.1 100000004864 10025055 Lung cancer non-small cell stage IV LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: CZ (Completed) DE (Prematurely Ended) GB (Prematurely Ended) HU (Completed) ES (Prematurely Ended) BE (Prematurely Ended) PL (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2011-003288-31 Sponsor Protocol Number: TUD-CELIM2-050 Start Date*: 2012-06-04
    Sponsor Name:Technical University Dresden
    Full Title: Open, randomized, multicenter phase II trial with cetuximab /5-FU/FA/irinotecan or cetuximab/5-FU/FA /irinotecan/oxaliplatin in ras wild type patients or with irinotecan/oxaliplatin/5-FU/FA with or...
    Medical condition: The aim of this study is to investigate the following schedules for efficacy with regard to response rate in neoadjuvant treatment of patients with non-resectable liver metastases: - Cetuximab/FOL...
    Disease: Version SOC Term Classification Code Term Level
    19.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10052362 Metastatic colorectal cancer LLT
    19.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10027457 Metastases to liver PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2012-002564-27 Sponsor Protocol Number: STH16037 Start Date*: 2013-01-31
    Sponsor Name:Sheffield Teaching Hospitals NHS Foundation Trust
    Full Title: Pilot open study of testosterone replacement in non-alcoholic steatohepatitis
    Medical condition: Non alcoholic fatty liver disease (NAFLD) in men with low serum testosterone levels
    Disease:
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2015-005385-38 Sponsor Protocol Number: GFT505-315-1 Start Date*: 2016-03-04
    Sponsor Name:Genfit SA
    Full Title: A Multicentre, Randomized, Double-Blind, Placebo-Controlled Phase III Study to Evaluate the Efficacy and Safety of Elafibranor in Patients with Non-Alcoholic Steatohepatitis (NASH) and fibrosis.
    Medical condition: Non-Alcoholic Steatohepatitis (NASH) and fibrosis
    Disease: Version SOC Term Classification Code Term Level
    20.0 10018065 - General disorders and administration site conditions 10016642 Fibrosis PT
    22.0 10019805 - Hepatobiliary disorders 10053219 Non-alcoholic steatohepatitis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Prematurely Ended) GB (Completed) DE (Completed) CZ (Prematurely Ended) SE (Completed) IT (Prematurely Ended) PT (Completed) NL (Completed) DK (Prematurely Ended) FI (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2012-000075-16 Sponsor Protocol Number: BAY88-8223/16216 Start Date*: 2012-06-20
    Sponsor Name:Bayer HealthCare AG
    Full Title: Radium-223 Dichloride (Alpharadin) in Castration-Resistant (Hormone-Refractory) Prostate Cancer Patients with Bone Metastasis
    Medical condition: Castrate Resistant Prostate Cancer/Hormone-Refractory Prostate Cancer patients with bone metastasis
    Disease: Version SOC Term Classification Code Term Level
    18.1 100000004864 10036916 Prostate cancer stage D LLT
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: SE (Completed) DE (Completed) NO (Completed) FI (Completed) BE (Completed) ES (Completed) CZ (Completed) IE (Completed) GB (Completed) IT (Completed) DK (Prematurely Ended) NL (Completed) AT (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  3  4  5  6  7  8  9  Next» Last»»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Mon May 20 02:45:58 CEST 2024 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA